Literature DB >> 24824646

Disclosure of funding sources and conflicts of interest in phase III surgical trials: survey of ten general surgery journals.

Valérie Bridoux1, Grégoire Moutel, Lilian Schwarz, Francis Michot, Christian Herve, Jean-Jacques Tuech.   

Abstract

BACKGROUND: Discussions regarding disclosure of funding sources and conflicts of interest (COI) in published peer-reviewed journal articles are becoming increasingly more common and intense. The aim of the present study was to examine whether randomized controlled trials (RCTs) published in leading surgery journals report funding sources and COI.
METHODS: All articles reporting randomized controlled phase III trials published January 2005 through December 2010 were chosen for review from ten international journals. We evaluated the number of disclosed funding sources and COI, and the factors associated with such disclosures.
RESULTS: From a review of 657 RCT from the ten journals, we discovered that presence or absence of a funding source and COI was disclosed by 47 % (309) and 25.1 % (165), respectively. Most articles in "International Committee of Medical Journal Editors (ICMJE)-affiliated journals" did not disclose COI. Disclosure of funding was associated with a journal impact factor >3 (51.7 vs 41.6 %; p < 0.01), statistician/epidemiologist involvement (64.2 vs 43.7 %; p < 0.001), publication after 2008 (52.9 vs 41.1 %; p < 0.01), and the journal being ICMJE-affiliated (49.3 vs 40 %; p < 0.05). Conflict of interest disclosure was associated with publication after 2008 (38.7 vs 11.3 %; p < 0.001), and with the journal not being affiliated with ICMJE (36.9 vs 21.3 %; p < 0.001).
CONCLUSIONS: Of the published studies we investigated, over half did not disclose funding sources (i.e., whether or not there was a funding source), and almost three quarters did not disclose whether COI existed. Our findings suggest the need to adopt best current practices regarding disclosure of competing interests to fulfill responsibilities to readers and, ultimately, to patients.

Entities:  

Mesh:

Year:  2014        PMID: 24824646     DOI: 10.1007/s00268-014-2580-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  41 in total

1.  Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors:  T Bodenheimer
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

Review 2.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

3.  Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.

Authors:  Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux
Journal:  CMAJ       Date:  2004-02-17       Impact factor: 8.262

4.  Disclosure of conflicts of interest by authors of clinical trials and editorials in oncology.

Authors:  Rachel P Riechelmann; Lisa Wang; Aoife O'Carroll; Monika K Krzyzanowska
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

5.  Understanding financial conflicts of interest.

Authors:  D F Thompson
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

6.  Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.

Authors:  Mark A Malangoni; James Song; Janet Herrington; Shurjeel Choudhri; Peter Pertel
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

7.  Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection.

Authors:  H M C Shantha Kumara; I Kirman; D Feingold; V Cekic; A Nasar; T Arnell; E Balik; A Hoffman; R Baxter; S Conte; R L Whelan
Journal:  Eur J Surg Oncol       Date:  2008-09-07       Impact factor: 4.424

8.  A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.

Authors:  E Steve Woodle; M Roy First; John Pirsch; Fuad Shihab; A Osama Gaber; Paul Van Veldhuisen
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

9.  Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients.

Authors:  Albert E Yellin; Jeffrey Johnson; Iliana Higareda; Blaise L Congeni; Antonio C Arrieta; Doreen Fernsler; Joseph West; Richard Gesser
Journal:  Am J Surg       Date:  2007-09       Impact factor: 2.565

10.  Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.

Authors:  Lisa Bero; Fieke Oostvogel; Peter Bacchetti; Kirby Lee
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

View more
  5 in total

1.  Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency.

Authors:  Adam G Dunn; Enrico Coiera; Kenneth D Mandl; Florence T Bourgeois
Journal:  Res Integr Peer Rev       Date:  2016-05-03

2.  The reporting of funding in health policy and systems research: a cross-sectional study.

Authors:  Assem M Khamis; Lama Bou-Karroum; Maram B Hakoum; Mounir Al-Gibbawi; Joseph R Habib; Fadi El-Jardali; Elie A Akl
Journal:  Health Res Policy Syst       Date:  2018-08-17

3.  Conflicts of interest in randomised controlled surgical trials: systematic review and qualitative and quantitative analysis.

Authors:  Pascal Probst; Kathrin Grummich; Ulla Klaiber; Phillip Knebel; Alexis Ulrich; Markus W Büchler; Markus K Diener
Journal:  Innov Surg Sci       Date:  2016-04-22

4.  Identifying competing interest disclosures in systematic reviews of surgical interventions and devices: a cross-sectional survey.

Authors:  Jiajie Yu; Guanyue Su; Allison Hirst; Zhengyue Yang; You Zhang; Youping Li
Journal:  BMC Med Res Methodol       Date:  2020-10-19       Impact factor: 4.615

5.  Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance.

Authors:  Maram B Hakoum; Nahla Jouni; Eliane A Abou-Jaoude; Divina Justina Hasbani; Elias A Abou-Jaoude; Luciane Cruz Lopes; Mariam Khaldieh; Mira Zein Hammoud; Mounir Al-Gibbawi; Sirine Anouti; Gordon Guyatt; Elie A Akl
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.